AskBio Declares Independence After Bayer Acquisition
Will Not Be Hamstrung By Bureaucracy
Executive Summary
The gene therapy specialist's CEO Sheila Mikhail tells Scrip she is excited to be getting access to the German group's late-stage clinical and operational expertise while keeping AskBio's entrepreneurial culture and carrying on as an autonomous company on an arm’s-length basis.
You may also be interested in...
Bayer Bids To Become Cell Therapy Manufacturing Leader
The German group has invested $250m into a facility at its campus in Berkeley, CA to produce cell therapies from its own portfolio and for other companies in the space who are looking to tackle the perennial issue of manufacturing.
Bayer Heralds Potential Of BlueRock Parkinson's Stem Cell Therapy
Bayer pharma research head Christian Rommel has told Scrip he was excited about the Phase I data on Parkinson's disease prospect bemdaneprocel, which is comprised of dopamine-producing neurons derived from pluripotent stem cells, but also advocated caution at this early stage.
Bayer's High Hopes For Huntington's Gene Therapy As Novartis’s Branaplam Stumbles
When the German major bought AskBio a couple of years ago, one of its assets was a gene therapy for Huntington’s, a devastating disease that leads to complete physical and mental deterioration. That asset, BV-101, is about to enter the clinic.